There are 2949 resources available
709P - Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study
Presenter: Bradley McGregor
Session: E-Poster Display
Resources:
Abstract
710P - Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses
Presenter: Chung-Han Lee
Session: E-Poster Display
Resources:
Abstract
711P - Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
Presenter: Laurence Albiges
Session: E-Poster Display
Resources:
Abstract
712P - Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial
Presenter: Jean Courcier
Session: E-Poster Display
Resources:
Abstract
713P - Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214
Presenter: Meredith Regan
Session: E-Poster Display
Resources:
Abstract
714P - Time to deterioration in quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214
Presenter: David Cella
Session: E-Poster Display
Resources:
Abstract
715P - Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC)
Presenter: Bilal Siddiqui
Session: E-Poster Display
Resources:
Abstract
716P - Optimizing ipilimumab in metastatic renal cell carcinoma: SAKK 07/17 study
Presenter: Frank Stenner-Liewen
Session: E-Poster Display
Resources:
Abstract
717P - Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk
Presenter: Toni Choueiri
Session: E-Poster Display
Resources:
Abstract
718P - A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
Presenter: Thomas Powles
Session: E-Poster Display
Resources:
Abstract